Heber Biotec S.A. was funded in 1991 as a specialized biotechnology company that commercializes the products developed by the Center for Genetic Engineering and Biotechnology. The company has open markets for its product portfolio through more than 400 sanitary registers approved in more than 45 countries. During the last 5 years the product portfolio have been diversify including currently placental products, chemically synthesized products and generic pharma products additional to the biotechnology recombinant products. The advance technological culture reached by the Center for Genetic Engineering and Biotechnology made possible to emerge new transfer of technologies activities involving, patent licenses, technical assistance and technological training activities among others sophisticated technological services that have been negotiated by Heber Biotec S.A. in productive Joint Ventures and other modalities of technical cooperation. This technological view has projected a strong division of developing technologies that goes beyond the introduction of new products but also to diversifying pharmaceutical forms that allows used the active principles in new applications. The wide experience in the regulations norms for pharmaceutical products in 4 continents has developed a regulatory and clinical trial group that permits to extent the results not only for Cuba that shows excellent health indexes but for a very wide international registration activity. The results allow launching novel applications that have started changing the expectation of cure of some serious diseases. Huge perspective also comes from the agriculture applications directed to improve the crops yields, to decrease the chemical contamination an preserve a more ecological environment.